CJ 바이오사이언스

311690KOSDAQView the 바이오 R&D sectorTheme Bio & healthcare

3,775KRWMarket close of 10/21 (Wed)

Up +1.48%+55KRWMarket close of 10/21 (Wed)

Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/22 (Thu)3,690KRWDown -2.25%

Preliminary · just after the close · replaced by official KRX data tomorrow morning

Open: 3,720
High: 3,900
Low: 3,645
Day range: Day range low 3,645 high 3,900, open 3,720, close 3,775, previous close 3,720
Volume: 0×10K shares
: 13.48 million KRW 0.59× the 20-session average

Market close of 10/21 (Wed)

Where it sits in the 1-year range

9% of the way up from the lowest close in 1 year (252 sessions) · -62.2% from the high

Something to check

1 to check: operating loss

Free · no sign-inSource from 2021-05-17

Points to check

Earningsto check-23.5B KRWOperating income over the last four quarters -23.5B KRW (loss)Operating income, 8 quarters
Recent filingsnot verifiedOutside filing data coverage, so not verified
Foreign & institutionalnot verifiedOutside investor-flow coverage, so not verified

The other 3 are within the usual range

Daily move+1.48%usual range
Trading value0.6×usual range
Data date10/21 (Wed)Market close

See the full check report

Key figures

: 49.3B KRW
: Not computed — loss-making, or the four quarters are incomplete
: 1.03×
: 13,065,462 shares
Trading value ratio: 0.59× the 20-session average0.6×

52-week closing rangeNow 3,775

3,1859,990

Financials filed 2026-05-15 · KRX·DART

Something to check

1 to check: operating loss

Earningsto checkQuarterly operating income bars (6); the four dark bars make up the sum-23.5B KRW
Recent filingsnot verifiedOutside filing data coverage, so not verified
Foreign & institutionalnot verifiedOutside investor-flow coverage, so not verified
Daily moveusual range+1.48% on the reference date, placed against the usual ±0.80% band1.8×
Trading valueusual range0.59× the 20-session average0.6×
Data dateusual rangeMarket close data of 2026-10-21

Quarterly results · Q1 2026

Source: DART financials (Q4 derived as annual − three quarters) · Amended filing reflected

Revenue783.07 million KRWRevenue bars for the last 8 quarters; the dark bar is this quarter
vs. year ago
-14.2%
vs. prior quarter
-37.8%
Operating income-5.3B KRWOperating income bars for the last 8 quarters; the dark bar is this quarter
vs. year ago
Still a loss
vs. prior quarter
Still a loss
Operating margin-682.2%Operating margin bars for the last 8 quarters; the dark bar is this quarter
vs. year ago
+40.5 pp
vs. prior quarter
-272.2 pp

Quarterly operating income trend

As of the latest official close · 2026-10-21Valuation filing date · 2026-05-15

2021Q1 -2.1B KRW2026Q1 -5.3B KRWQ4 values are derived as the annual figure minus Q1–Q3. The value table marks them in the Type column.

Same sector · 바이오 R&D

· 33 of 64 stocks up, preferred shares excluded · trading value 215.2B KRW

Same sector · top by trading value
Stock	20D	Change	Trading value
알테오젠	Close over the last 20 sessions -5.5%	Up +3.90%	60.7B KRW
올릭스	Close over the last 20 sessions -6.4%	Up +9.53%	26.1B KRW
디앤디파마텍	Close over the last 20 sessions -6.0%	Up +6.65%	22.0B KRW
리가켐바이오	Close over the last 20 sessions -14.3%	Up +2.00%	12.9B KRW
프로티나	Close over the last 20 sessions +35.7%	Up +7.23%	11.0B KRW

Schedule

Next data 10/23 (Fri) after 08:50

Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 85% of trading value, about 92% of market capitalisation. Coverage status →

For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.